20321 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
#302Method of treating pancreatitis
#303Liposome combination and the use thereof
#304Substituted porphyrins
#305Substituted Porphyrins
#306Uses of porphyrin compounds
#307Detection, monitoring and treatment of cancer
#308Removal of fat cells by PDT
#309Cancer therapy
#310Cancer gene therapeutic drug
#311Method for delivering hydrophobic drugs via nanocrystal formulations
#312Cancer gene therapeutic drug
#313MULTIFUNCTIONAL CORE FOR MOLECULAR IMAGING AND TARGETED DELIVERY OF MACROMOLECULES AND DRUGS
#314Use of green porphyrins to treat neovasculature in the eye
#315Drug delivery systems for photodynamic therapy
#316Method of bioimaging using nanocrystals of fluorescent dyes
#317PDT treatment method for cellulites and cosmetic use
#318Methods for treating ocular neovascular diseases
#319Methods of using nitroxides in conjuction with photosensitzers and sonosensitizers
#320Topical skin compositions, their preparation, and their use
#321Method for treating neovascularization
#322Sapphyrins and uses thereof
#323Enhanced occlusive effect photodynamic therapy
#324Radiosensitizer
#325Methods and compositions for treating conditions of the eye
#326Polycarboxylated porphyrins and use thereof in treatment of metal toxicities
#327Novel use of porphyrin derivatives
#328Ophthalmic drug delivery system using polymer micell
#329Ophthalmic drug delivery system using polymer micelle
#330Superoxide dismutase mimics for the treatment of ocular disorders and diseases
#331Substituted porphyrins
#332Composition and method for treating hyperproliferative diseases
#333Pharmaceutical composition for inhibiting influenza virus infection and reproduction
#334Photosensitizer formulations and their use
#335Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor through administration of a pyrophosphate analog
#336Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection
#337Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent
#338Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions
#339Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
#340Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog
#341Novel association, a method of its preparation and its uses
#342Pharmaceutical nitrones
#343Use of targeted oxidative therapeutic formulation in treatment of cancer
#344Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
#345Use of targeted oxidative therapeutic formulation in bone regeneration
#346Photodynamic therapy in conjunction with intraocular implants
#347Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine
#348Chlorophyll and its derivatives for cancer photodynamic therapy
#349Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
#350Methods and compositions for improving photodynamic therapy through administration of lipids
#351Method of photodynamic diagnosis for vascular diseases
#352Method for enhanced photodynamic therapy
#353Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
#354Use of green porphyrins to treat neovasculature in the eye
#355Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
#356Auger effect-based cancer therapy method
#357Porphyrins with virucidal activity
#358Medicinal targeted local lipolysis
#359Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) porphine
#360Indole derivative
#361Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same
#362Formulation of ear drops and methods for delivery thereof for treating upper respiratory infections
#363Method of treating subject exposed to radiation in space
#364Combinational fendiline formulations and uses thereof
#365Nutritional supplement compositions containing C60-fullerene-phytonutrient-triglyceride complexes for sub-cellular phytonutrient delivery
#366Anti-aging nutritional supplement compositions for animals